Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids

Vehmanen, Leena; Saarto, Tiina; Blomqvist, Carl; Taskinen, Marja‐Riitta; Elomaa, Inkeri

doi:10.1038/sj.bjc.6601979

Cited by 22 publications

(19 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Monika Sharma et al investigate the longitudinal effect of chemotherapy on lipids in the same group of patients by monitoring the serum lipid profiles of 12 breast cancer patients throughout their multi-agent chemotherapy treatments have obtained the similar results of lipids changes before and after chemotherapy [ 37 ]. Some hypotheses implicate that chemotherapy may directly cause endothelial dysfunction, leading to cytokine alterations, and hence may cause development of lipids [ 38 , 39 ]. Further evidence show that cancer-associated adipocytes modify the cancer cell phenotype leading to a more aggressive behavior [ 40 ].…”

Section: Discussionmentioning

confidence: 99%

Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy

Liu

et al. 2018

Lipids Health Dis

View full text Add to dashboard Cite

BackgroundThe lipid profile status among breast cancer patients at initial diagnosis and during chemotherapy remain controversial. The aim of this study is to study the status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy.MethodsWe conducted a retrospective cohort study of the status of the lipid and lipoprotein in 1054 primarily diagnosed breast cancer patients and 2483 normal controls with age stratification, from July 2015 to October 2016. At the same time, the status of lipid and lipoprotein were also analyzed among 394 breast cancer patients before and after adjuvant chemotherapy.ResultsThe incidence of dyslipidemia was significantly lower in breast cancer group(42.98%) compared to normal group(58.28%)(P < 0.001). The levels of total cholesterol (TC), triglycerides (TG), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C) among breast cancer group were significantly lower compared to normal control group (P < 0.05). With age stratification, the levels of TC and LDL-C in breast cancer group were still significantly lower than those in control group (P < 0.001). And the levels of TC, TG, LDL-C, apolipoprotein B were significantly higher among post chemotherapeutic patients compared to prechemotherapeutic patients, however HDL-C and Apo-A1 levels were contrary.ConclusionsBreast cancer patients have lower incidence of dyslipidemia compared to normal populations. However, the situation of dyslipidemia may become worsened after chemotherapy. Therefore, lipid monitoring and dyslipidemia prevention and treatment should be conducted for breast cancer patients at initial diagnosis and during chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy

Liu

et al. 2018

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…Tamoxifen has been well-reported to lower total- and LDL-cholesterol [ 33 – 36 ] as early as 3 months after treatment initiation [ 34 , 35 ]. Further, the administration of adjuvant tamoxifen after chemotherapy has been observed to reverse dyslipidaemias in premenopausal patients [ 30 ]. In the present study, a significant proportion of patients were found to have dyslipidaemias after chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy

Park

Pang

et al. 2017

BMC Women's Health

View full text Add to dashboard Cite

BackgroundAdjuvant chemotherapy improves outcome of patients with early breast cancer. However, chemotherapy may be associated with long term toxicities. In this retrospective cohort study, the objectives were to determine body weight, body mass index (BMI), blood pressure and fasting lipids levels of young premenopausal Chinese breast cancer patients after adjuvant chemotherapy. Potential factors associated with these parameters were identified.MethodsEligibility criteria include premenopausal Chinese patients who were diagnosed to have stage I-III breast cancer within 3–10 years, age < 45 and having received adjuvant chemotherapy at the time of breast cancer diagnosis. Information at initial breast cancer diagnosis were retrieved from patients’ medical records and include age at diagnosis, tumor characteristics, anti-cancer treatments, blood pressure and body weight and height. At study entry, all patients had additional background demographics collected, as well as blood pressure, body weight and fasting serum lipid profiles measured. Incidence of chemotherapy-related amenorrhoea (CRA) and menopause were determined. Factors associated with weight gain, hypertension and dyslipidaemias were analyzed.ResultsTwo hundred and eighty patients were studied. The median age at breast cancer diagnosis was 41 years (range: 24–45). The median time from breast cancer diagnosis to study entry was 5.0 years. The median age at study entry was 46.5 years (range: 28–54). 91.1% developed CRA; 48.9% had become menopausal and 10% were peri-menopausal. Between initial breast cancer diagnosis and the time of study entry, the median weight gain was 1.8 kg; 63.2% gained weight by >2%; 52.1% were overweight/obese; 30.7% had hypertension. Abnormal total-cholesterol and LDL-cholesterol occurred in 34.3% and 56.1% respectively. On multivariate analyses, older age was associated with reduced risk while occurrence of CRA and having received taxane-containing regimens were associated with increased risk of weight gain. Oestrogen-receptor positivity was associated with reduced risk while overweight/obese statuses were associated with increased risk of hypertension. Use of tamoxifen was associated with reduced risk of abnormal LDL-cholesterol. Weight gain, overweight/obese, older age, progression to post/peri-menopausal status at study entry, having received corticosteroid premedication before adjuvant chemotherapy and having received taxane-containing adjuvant chemotherapy were associated with increased risk of dyslipidaemias.ConclusionAmong young premenopausal Chinese breast cancer patients who had received adjuvant chemotherapy, the current study has revealed that although there was only a median weight gain of 1.8 kg, there was a nearly 60% increase in abnormal BMI. Further, a significant proportion of patients were detected to have hypertension and dyslipidaemias. Interventional studies with lifestyle modifications are warranted.Electronic supplementary materialThe online version of this article (doi:10.1186/s12905-017-0409-8) contains sup...

show abstract

“…Premenopausal patients with breast cancer also experience detrimental effects from chemotherapy on conditions contributing to MetS; in particular, their body weight may increase, leading to a higher body mass index (BMI) and larger measures of central obesity . Furthermore, chemotherapy in premenopausal patients with breast cancer may induce premature menopause, which is associated with increases in body fat and cholesterol and TRI levels . Therefore, it is important to monitor changes in MetS components in both premenopausal and postmenopausal patients with breast cancer during chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

“…1 Furthermore, chemotherapy in premenopausal patients with breast cancer may induce premature menopause, which is associated with increases in body fat and cholesterol and TRI levels. 1,13 Therefore, it is important to monitor changes in MetS components in both premenopausal and postmenopausal patients with breast cancer during chemotherapy. Understanding the potential detrimental effects of chemotherapy on MetS components and metabolic health is critical to controlling future chronic health problems, improving survival, and enhancing quality of life as clinicians develop survivorship care plans for patients with breast cancer.…”

Section: Introductionmentioning

confidence: 99%

An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy

Dieli‐Conwright

Wong

Waliany

et al. 2016

Cancer

107

View full text Add to dashboard Cite

BACKGROUND We sought to determine the effect of chemotherapy on the development of metabolic syndrome (MetS) in premenopausal and postmenopausal women undergoing (neo) adjuvant therapy for early stage breast cancer. METHODS Eighty-six women with early stage (I-III) breast cancer who were free from clinically diagnosed MetS (defined as three out of five components of MetS) were prospectively tested for presence of the five components of MetS within one week before initiating and after completing (neo) adjuvant chemotherapy. The five components of MetS measured were waist circumference, blood pressure, and fasting levels of blood glucose, triglycerides, and high-density lipoprotein cholesterol. Anthropometrics (body weight, percent body fat, fat mass), lipid profile (total cholesterol, low-density lipoprotein cholesterol), glucose metabolism (insulin, homeostatic model assessment-insulin resistance, glycated hemoglobin), and inflammation (C-reactive protein) were also examined before initiating and after completing treatment. RESULTS The study included 46 premenopausal and 40 postmenopausal women. All individual MetS components and overall MetS score were statistically significantly increased (p<0.01) after chemotherapy. Body weight, percent body fat, fat mass, lipids, glucose metabolism, and inflammation were also statistically significantly increased (p<0.01). CONCLUSION A 12–18 week course of chemotherapy statistically significantly increases MetS and related anthropometrics, biomarkers of glucose metabolism, and inflammation in early stage breast cancer patients with no pre-existing MetS. Lifestyle interventions such as diet and exercise may be preventive approaches to employ during chemotherapy to reduce the onset of MetS in breast cancer patients.

show abstract

Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids

Cited by 22 publications

References 51 publications

Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy

Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy

Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy

An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy

Contact Info

Product

Resources

About